FDA's New Endotoxin Test Guidance for Human Parenteral Drugs, Biological Products and Medical Devices

Live, Interactive Training Webinar

Date: September 24, 2013
Time: 1:00pm - 3:00pm ET

Instructor: Barry A.Friedman Ph.D.
Click Here to Register for this Interactive, Live Webinar

The FDA posted on their web site on Tuesday, July 12, 2011 a notice that they had withdrawn the 1987 Guideline on Validation of the Limulus Amebocyte Lysate Test as an End Product Endotoxin Test for Human Parenteral Drugs, Biological Products and Medical Devices. They advised that the 1987 Guideline is considered obsolete and does not reflect the Agency's current thinking on the topic.
In lieu of this document, the FDA advised that they would be issuing a Guidance for Industry on Pyrogen and Endotoxins Testing: Questions and Answers during the November/ December 2011 timeframe. After much delay, this NEW Guidance was just released in June 2012.
The FDA referenced, however, three documents that they believe have more than offset the previous FDA Guidance that was withdrawn. They advise that these documents be referenced for the fundamental principles of the gel clot, photometric and kinetic test methods.
This NEW, revised Guidance supplements the above three documents and addresses those issues that may be subject to misinterpretation, not covered in compendial procedures or in the previously available Guidance document.
The objective of this live training webinar is to explore the NEW Guidance for Industry on Pyrogen and Endotoxins Testing which addresses those issues that may be subject to misinterpretation, and are not covered in compendial procedures or in the currently available Guidance documents and how they impact testing within the typical Quality Control laboratory.

Learning Benefits:
-Provide a review of the current testing requirements.
-Understanding what happened to the old 87/91 LAL Guidance for Industry document.
-Learn what has replaced it and why.
-Learn of common issue misunderstandings and misinterpretations.
-Determine who comprise the Agency Guidance team involved within this new proposed Guidance.
-Learn of the documents supporting this new Guidance.
-Learn about sampling, storage, handling and pooling.
-How does one transition from one bacterial endotoxin test to another.
-Determine when the Rabbit Pyrogen Test is appropriate to use in lieu of the LAL.
-Understand the FDA's expectation for screening of therapeutic products.

Webinar outline and time breakdown:

Date: September 24, 2013

*Please note all times are Eastern Standard Time

This live training webinar includes the following for each registered attendee:

• A copy of the presentation slides
• A certificate of participation for attendee training records

Who should attend:
The following individuals or disciplines will benefit from attending this Webinar:

• Quality Assurance personnel
• Quality Control personnel
• Research & Development
• Regualtory Affairs Professionals
• Validation
• Auditors